Opendata, web and dolomites

MoTriColor SIGNED

Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MoTriColor project word cloud

Explore the words cloud of the MoTriColor project. It provides you a very rough idea of what is the project "MoTriColor" about.

sound    scientific    therapy    single    liquid    risk    previously    immunotherapeutic    colorectal    advantage    braf    expression    classification    subgroups    select    rationale    treatment    monitoring    poor    experimental    translated    arm    cancer    subtypes    tolerability    mutant    treatments    tgf    ffpe    centre    tumour    ly2157299    solid    gene    molecularly    l1    drug    efficacy    brafm    biological    biomarkers    basis    presenting    safety    routine    signalling    endpoint    patterns    pd    heterogeneous    chemotherapy    diagnostic    beta    clinical    phenotypes    50    mutation    prognosis    consequently    vinorelbine    outcomes    signature    primary    assays    crc    inhibitor    matching    bevacizumab    disease    progression    predict    cms4    perform    therapies    combination    platform    benefit    beginning    types    free    survival    biopsies    label    anti    retrospective    reveal    preclinical    worldwide    profiles    equivalent    mpdl3280a    stage    molecular    msi    populations    deregulated    patients    potentially   

Project "MoTriColor" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON 

Organization address
address: CALLE NAZARET 115-117
city: BARCELONA
postcode: 8035
website: http://www.vhio.net

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.motricolor.eu
 Total cost 5˙996˙992 €
 EC max contribution 5˙996˙992 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2014-two-stage
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-10-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON ES (BARCELONA) coordinator 1˙147˙455.00
2    Agendia NV NL (Amsterdam) participant 905˙250.00
3    INSTITUT CATALA D'ONCOLOGIA ES (L'HOSPITALET DEL LLOBREGAT) participant 829˙320.00
4    STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS NL (AMSTERDAM) participant 771˙611.00
5    UNIVERSITA DEGLI STUDI DI TORINO IT (TORINO) participant 682˙125.00
6    EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL BE (Brussels) participant 580˙500.00
7    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 277˙268.00
8    FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA ES (VALENCIA) participant 271˙424.00
9    UNIVERSITA DEGLI STUDI DELLA CAMPANIA LUIGI VANVITELLI IT (CASERTA) participant 266˙143.00
10    L'AZIENDA SOCIO SANITARIA TERRITORIALE (ASST) GRANDE OSPEDALE METROPOLITANO NIGUARDA IT (MILANO) participant 265˙896.00
11    AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA IT (MILANO) participant 0.00

Map

 Project objective

Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease with distinct molecular subtypes. These subtypes have different biological processes at the basis of their disease and consequently their prognosis and responses to therapy are also different. We have previously developed molecular diagnostic assays using a single platform on routine FFPE tumour biopsies. These assays identify gene expression profiles with distinct prognosis and drug response phenotypes (CMS4/c-type, BRAF mutant-like, and MSI-like). Our overall objective is to develop targeted therapies more effective than the current therapies that do not take advantage of molecular classification of the disease to select patients for therapy. We therefore propose to perform 3 two-stage single arm multi-centre open-label phase II studies based on solid preclinical evidence and a sound scientific rationale for these subgroups of CRC patients: 1) combination of chemotherapy and a TGF-βR inhibitor (LY2157299) in patients presenting a C-type signature; 2) vinorelbine in patients with a BRAFm-like signature; and 3) an immunotherapeutic anti-PD-L1 drug (MPDL3280A) in combination with bevacizumab in patients with a MSI-like signature. The primary objectives of these studies are to determine the clinical efficacy (progression-free survival as primary endpoint), safety and tolerability of the experimental treatments in these molecularly selected populations. Mutation analysis at the beginning of treatment and monitoring by liquid biopsies might reveal further biomarkers that predict response in retrospective analysis. The project outcomes may have a significant impact in CRC patients with poor-risk prognosis worldwide as 40-50% of them present gene expression profiles matching one of the 3 approaches. Around 40,000 European CRC patients may potentially benefit from the results. Also, these may be translated to other cancer types with equivalent gene expression patterns/deregulated signalling pathways.

 Publications

year authors and title journal last update
List of publications.
2018 Anna Truini, Giovanni Germano, Alberto Bardelli
Inactivation of DNA repair—prospects for boosting cancer immune surveillance
published pages: 91, ISSN: 1756-994X, DOI: 10.1186/s13073-018-0603-9
Genome Medicine 10/1 2020-04-22
2019 Alessio Amatu, Marta Schirripa, Federica Tosi, Sara Lonardi, Katia Bencardino, Erica Bonazzina, Laura Palmeri, Damiano Alfio Patanè, Elio Gregory Pizzutilo, Benedetta Mussolin, Francesca Bergamo, Giulia Alberti, Rossana Intini, Letizia Procaccio, Marco Arese, Silvia Marsoni, Michele Nichelatti, Vittorina Zagonel, Salvatore Siena, Alberto Bardelli, Fotios Loupakis, Federica Di Nicolantonio, Andrea
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
published pages: , ISSN: 2234-943X, DOI: 10.3389/fonc.2019.00622
Frontiers in Oncology 9 2020-04-22
2019 Andrea Sartore‐Bianchi, Alessio Amatu, Luca Porcu, Silvia Ghezzi, Sara Lonardi, Francesco Leone, Francesca Bergamo, Elisabetta Fenocchio, Erika Martinelli, Beatrice Borelli, Federica Tosi, Patrizia Racca, Emanuele Valtorta, Emanuela Bonoldi, Cosimo Martino, Caterina Vaghi, Giovanna Marrapese, Fortunato Ciardiello, Vittorina Zagonel, Alberto Bardelli, Livio Trusolino, Valter Torri, Silvia Marsoni
HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer
published pages: 1395-1402, ISSN: 1083-7159, DOI: 10.1634/theoncologist.2018-0785
The Oncologist 24/10 2020-04-22
2019 Luca Lazzari, Giorgio Corti, Gabriele Picco, Claudio Isella, Monica Montone, Pamela Arcella, Erika Durinikova, Eugenia R. Zanella, Luca Novara, Fabiane Barbosa, Andrea Cassingena, Carlotta Cancelliere, Enzo Medico, Andrea Sartore-Bianchi, Salvatore Siena, Mathew J. Garnett, Andrea Bertotti, Livio Trusolino, Federica Di Nicolantonio, Michael Linnebacher, Alberto Bardelli, Sabrina Arena
Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer
published pages: 6243-6259, ISSN: 1078-0432, DOI: 10.1158/1078-0432.ccr-18-3440
Clinical Cancer Research 25/20 2020-04-22
2019 Elena Garralda, Rodrigo Dienstmann, Alejandro Piris-Giménez, Irene Braña, Jordi Rodon, Josep Tabernero
New clinical trial designs in the era of precision medicine
published pages: 549-557, ISSN: 1574-7891, DOI: 10.1002/1878-0261.12465
Molecular Oncology 13/3 2020-04-22
2018 J Seoane, L De Mattos-Arruda, E Le Rhun, A Bardelli, M Weller
Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases
published pages: 211-218, ISSN: 0923-7534, DOI: 10.1093/annonc/mdy544
Annals of Oncology 30/2 2020-04-22
2019 Giorgio Corti, Alice Bartolini, Giovanni Crisafulli, Luca Novara, Giuseppe Rospo, Monica Montone, Carola Negrino, Benedetta Mussolin, Michela Buscarino, Claudio Isella, Ludovic Barault, Giulia Siravegna, Salvatore Siena, Silvia Marsoni, Federica Di Nicolantonio, Enzo Medico, Alberto Bardelli
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology
published pages: 91-101.e3, ISSN: 1533-0028, DOI: 10.1016/j.clcc.2019.02.008
Clinical Colorectal Cancer 18/2 2020-04-22
2019 Gianluca Mauri, Andrea Sartore-Bianchi, Antonio-Giampiero Russo, Silvia Marsoni, Alberto Bardelli, Salvatore Siena
Early-onset colorectal cancer in young individuals
published pages: 109-131, ISSN: 1574-7891, DOI: 10.1002/1878-0261.12417
Molecular Oncology 13/2 2020-04-22
2019 Giulia Siravegna, Andrea Sartore-Bianchi, Rebecca J. Nagy, Kanwal Raghav, Justin I. Odegaard, Richard B. Lanman, Livio Trusolino, Silvia Marsoni, Salvatore Siena, Alberto Bardelli
Plasma HER2 ( ERBB2 ) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
published pages: 3046-3053, ISSN: 1078-0432, DOI: 10.1158/1078-0432.ccr-18-3389
Clinical Cancer Research 25/10 2020-04-22
2019 Aparna R. Parikh, Ignaty Leshchiner, Liudmila Elagina, Lipika Goyal, Chaya Levovitz, Giulia Siravegna, Dimitri Livitz, Kahn Rhrissorrakrai, Elizabeth E. Martin, Emily E. Van Seventer, Megan Hanna, Kara Slowik, Filippo Utro, Christopher J. Pinto, Alicia Wong, Brian P. Danysh, Ferran Fece de la Cruz, Isobel J. Fetter, Brandon Nadres, Heather A. Shahzade, Jill N. Allen, Lawrence S. Blaszkowsky, Jeffr
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
published pages: 1415-1421, ISSN: 1078-8956, DOI: 10.1038/s41591-019-0561-9
Nature Medicine 25/9 2020-04-22
2019 Giuseppe Rospo, Annalisa Lorenzato, Nabil Amirouchene-Angelozzi, Alessandro Magrì, Carlotta Cancelliere, Giorgio Corti, Carola Negrino, Vito Amodio, Monica Montone, Alice Bartolini, Ludovic Barault, Luca Novara, Claudio Isella, Enzo Medico, Andrea Bertotti, Livio Trusolino, Giovanni Germano, Federica Di Nicolantonio, Alberto Bardelli
Evolving neoantigen profiles in colorectal cancers with DNA repair defects
published pages: 42, ISSN: 1756-994X, DOI: 10.1186/s13073-019-0654-6
Genome Medicine 11/1 2020-04-22
2018 G Siravegna, A Bardelli
Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer
published pages: 157-159, ISSN: 0923-7534, DOI: 10.1093/annonc/mdy525
Annals of Oncology 30/2 2020-04-22
2019 Nicole M. Reilly, Luca Novara, Federica Di Nicolantonio, Alberto Bardelli
Exploiting DNA repair defects in colorectal cancer
published pages: 681-700, ISSN: 1574-7891, DOI: 10.1002/1878-0261.12467
Molecular Oncology 13/4 2020-04-22
2018 Giovanni Germano, Nabil Amirouchene-Angelozzi, Giuseppe Rospo, Alberto Bardelli
The Clinical Impact of the Genomic Landscape of Mismatch Repair–Deficient Cancers
published pages: 1518-1528, ISSN: 2159-8274, DOI: 10.1158/2159-8290.cd-18-0150
Cancer Discovery 8/12 2020-04-22
2019 G Siravegna, B Mussolin, T Venesio, S Marsoni, J Seoane, C Dive, N Papadopoulos, S Kopetz, R B Corcoran, L L Siu, A Bardelli
How liquid biopsies can change clinical practice in oncology
published pages: , ISSN: 0923-7534, DOI: 10.1093/annonc/mdz227
Annals of Oncology 2020-04-22
2017 Andrea Sartore-Bianchi, Alessio Amatu, Erica Bonazzina, Stefano Stabile, Laura Giannetta, Giulio Cerea, Ilaria Schiavetto, Katia Bencardino, Chiara Funaioli, Riccardo Ricotta, Tiziana Cipani, Michele Schirru, Valentina Gambi, Laura Palmeri, Giulia Carlo-Stella, Francesca Rusconi, Sara Di Bella, Giovanni Burrafato, Andrea Cassingena, Emanuele Valtorta, Calogero Lauricella, Federica Pazzi, Alessandra Gambaro, Silvia Ghezzi, Giovanna Marrapese, Emiliana Tarenzi, Silvio Veronese, Mauro Truini, Angelo Vanzulli, Salvatore Siena
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience
published pages: 525-533, ISSN: 1776-2596, DOI: 10.1007/s11523-017-0505-6
Targeted Oncology 12/4 2020-04-22
2017 Giovanni Germano, Simona Lamba, Giuseppe Rospo, Ludovic Barault, Alessandro Magrì, Federica Maione, Mariangela Russo, Giovanni Crisafulli, Alice Bartolini, Giulia Lerda, Giulia Siravegna, Benedetta Mussolin, Roberta Frapolli, Monica Montone, Federica Morano, Filippo de Braud, Nabil Amirouchene-Angelozzi, Silvia Marsoni, Maurizio D’Incalci, Armando Orlandi, Enrico Giraudo, Andrea Sartore-Bianchi, Salvatore Siena, Filippo Pietrantonio, Federica Di Nicolantonio, Alberto Bardelli
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
published pages: , ISSN: 0028-0836, DOI: 10.1038/nature24673
Nature 2020-04-22
2018 Mariangela Russo, Simona Lamba, Annalisa Lorenzato, Alberto Sogari, Giorgio Corti, Giuseppe Rospo, Benedetta Mussolin, Monica Montone, Luca Lazzari, Sabrina Arena, Daniele Oddo, Michael Linnebacher, Andrea Sartore-Bianchi, Filippo Pietrantonio, Salvatore Siena, Federica Di Nicolantonio, Alberto Bardelli
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-018-04506-z
Nature Communications 9/1 2020-04-22
2017 Filippo Pietrantonio, Federica Di Nicolantonio, Alexa B Schrock, Jeeyun Lee, Sabine Tejpar, Andrea Sartore-Bianchi, Jaclyn F Hechtman, Jason Christiansen, Luca Novara, Niall Tebbutt, Giovanni Fucà, Carlotta Antoniotti, Seung Tae Kim, Danielle Murphy, Rosa Berenato, Federica Morano, James Sun, Bosun Min, Philip J Stephens, Marissa Chen, Luca Lazzari, Vincent A Miller, Robert Shoemaker, Alessio Amatu, Massimo Milione, Jeffrey S Ross, Salvatore Siena, Alberto Bardelli, Siraj M Ali, Alfredo Falcone, Filippo de Braud, Chiara Cremolini
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
published pages: , ISSN: 0027-8874, DOI: 10.1093/jnci/djx089
JNCI: Journal of the National Cancer Institute 109/12 2020-04-22
2017 E Sanz-Garcia, G Argiles, E Elez, J Tabernero
BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives
published pages: 2648-2657, ISSN: 0923-7534, DOI: 10.1093/annonc/mdx401
Annals of Oncology 28/11 2020-04-22
2017 S Siena, A Sartore-Bianchi, R Garcia-Carbonero, M Karthaus, D Smith, J Tabernero, E Van Cutsem, X Guan, M Boedigheimer, A Ang, B Twomey, B A Bach, A S Jung, A Bardelli
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer
published pages: 119-126, ISSN: 0923-7534, DOI: 10.1093/annonc/mdx504
Annals of Oncology 29/1 2020-04-22
2018 S Siena, A Sartore-Bianchi, S Marsoni, H I Hurwitz, S J McCall, F Penault-Llorca, S Srock, A Bardelli, L Trusolino
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
published pages: 1108-1119, ISSN: 0923-7534, DOI: 10.1093/annonc/mdy100
Annals of Oncology 29/5 2020-04-22
2018 Erika Martinelli, Teresa Troiani, Vincenzo Sforza, Giulia Martini, Claudia Cardone, Pietro Paolo Vitiello, Davide Ciardiello, Anna Maria Rachiglio, Nicola Normanno, Andrea Sartore-Bianchi, Silvia Marsoni, Alberto Bardelli, Salvatore Siena, Fortunato Ciardiello
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
published pages: e000299, ISSN: 2059-7029, DOI: 10.1136/esmoopen-2017-000299
ESMO Open 3/1 2020-04-22
2017 Daniele Oddo, Giulia Siravegna, Annunziata Gloghini, Claudio Vernieri, Benedetta Mussolin, Federica Morano, Giovanni Crisafulli, Rosa Berenato, Giorgio Corti, Chiara Costanza Volpi, Michela Buscarino, Monica Niger, Philip D Dunne, Giuseppe Rospo, Emanuele Valtorta, Alice Bartolini, Giovanni Fucà, Simona Lamba, Antonia Martinetti, Maria Di Bartolomeo, Filippo de Braud, Alberto Bardelli, Filippo Pietrantonio, Federica Di Nicolantonio
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
published pages: 347-352, ISSN: 0007-0920, DOI: 10.1038/bjc.2017.196
British Journal of Cancer 117/3 2020-04-22
2018 Clara Montagut, Guillem Argilés, Fortunato Ciardiello, Thomas T. Poulsen, Rodrigo Dienstmann, Michael Kragh, Scott Kopetz, Trine Lindsted, Cliff Ding, Joana Vidal, Jenifer Clausell-Tormos, Giulia Siravegna, Francisco J. Sánchez-Martín, Klaus Koefoed, Mikkel W. Pedersen, Michael M. Grandal, Mikhail Dvorkin, Lucjan Wyrwicz, Ana Rovira, Antonio Cubillo, Ramon Salazar, Françoise Desseigne, Cristina Nadal, Joan Albanell, Vittorina Zagonel, Salvatore Siena, Guglielmo Fumi, Giuseppe Rospo, Paul Nadler, Ivan D. Horak, Alberto Bardelli, Josep Tabernero
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses
published pages: e175245, ISSN: 2374-2437, DOI: 10.1001/jamaoncol.2017.5245
JAMA Oncology 4/4 2020-04-22
2018 Maider Ibarrola-Villava, Andrés Cervantes, Alberto Bardelli
Preclinical models for precision oncology
published pages: 239-246, ISSN: 0304-419X, DOI: 10.1016/j.bbcan.2018.06.004
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1870/2 2020-04-22
2018 G Mauri, K Bencardino, A Sartore-Bianchi, S Siena
Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer
published pages: 2143-2144, ISSN: 0923-7534, DOI: 10.1093/annonc/mdy306
Annals of Oncology 29/10 2020-04-22
2017 Federica Tosi, Elena Magni, Alessio Amatu, Gianluca Mauri, Katia Bencardino, Mauro Truini, Silvio Veronese, Luciano De Carlis, Giovanni Ferrari, Michele Nichelatti, Andrea Sartore-Bianchi, Salvatore Siena
Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis
published pages: e153-e163, ISSN: 1533-0028, DOI: 10.1016/j.clcc.2017.01.004
Clinical Colorectal Cancer 16/3 2020-04-22
2018 Giulia Siravegna, Luca Lazzari, Giovanni Crisafulli, Andrea Sartore-Bianchi, Benedetta Mussolin, Andrea Cassingena, Cosimo Martino, Richard B. Lanman, Rebecca J. Nagy, Stephen Fairclough, Giuseppe Rospo, Giorgio Corti, Alice Bartolini, Pamela Arcella, Monica Montone, Francesca Lodi, Annalisa Lorenzato, Alice Vanzati, Emanuele Valtorta, Giovanni Cappello, Andrea Bertotti, Sara Lonardi, Vittorina Zagonel, Francesco Leone, Mariangela Russo, Antonella Balsamo, Mauro Truini, Federica Di Nicolantonio, Alessio Amatu, Erica Bonazzina, Silvia Ghezzi, Daniele Regge, Angelo Vanzulli, Livio Trusolino, Salvatore Siena, Silvia Marsoni, Alberto Bardelli
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer
published pages: 148-162.e7, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2018.06.004
Cancer Cell 34/1 2020-04-22
2018 Giovanni Germano, Gianluca Mauri, Giulia Siravegna, Caroline Dive, Jackie Pierce, Federica Di Nicolantonio, Maurizio D\'Incalci, Alberto Bardelli, Salvatore Siena, Andrea Sartore-Bianchi
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer
published pages: 80-83, ISSN: 1533-0028, DOI: 10.1016/j.clcc.2017.10.017
Clinical Colorectal Cancer 17/1 2020-04-22
2017 Sjors In ’t Veld, Kim Duong, Mireille Snel, Anke Witteveen, Inès Beumer, Leonie Delahaye, Diederik Wehkamp, René Bernards, Annuska Glas, Sun Tian
A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype of Colorectal Cancers
published pages: 16, ISSN: 2571-5135, DOI: 10.3390/ht6040016
High-Throughput 6/4 2020-04-22
2018 Sara Mainardi, Antonio Mulero-Sánchez, Anirudh Prahallad, Giovanni Germano, Astrid Bosma, Paul Krimpenfort, Cor Lieftink, Jeffrey D. Steinberg, Niels de Wit, Samuel Gonçalves-Ribeiro, Ernest Nadal, Alberto Bardelli, Alberto Villanueva, Rene Bernards
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
published pages: 961-967, ISSN: 1078-8956, DOI: 10.1038/s41591-018-0023-9
Nature Medicine 24/7 2020-04-22
2018 Ludovic Barault, Alessio Amatu, Giulia Siravegna, Agostino Ponzetti, Sebastian Moran, Andrea Cassingena, Benedetta Mussolin, Chiara Falcomatà, Alexandra M Binder, Carmen Cristiano, Daniele Oddo, Simonetta Guarrera, Carlotta Cancelliere, Sara Bustreo, Katia Bencardino, Sean Maden, Alice Vanzati, Patrizia Zavattari, Giuseppe Matullo, Mauro Truini, William M Grady, Patrizia Racca, Karin B Michels, Salvatore Siena, Manel Esteller, Alberto Bardelli, Andrea Sartore-Bianchi, Federica Di Nicolantonio
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer
published pages: 1995-2005, ISSN: 0017-5749, DOI: 10.1136/gutjnl-2016-313372
Gut 67/11 2020-04-22
2017 G. Rospo, G. Corti, G. Crisafulli, L. Novara, A. Bardelli
Tracking colorectal cancer evolution in time and space
published pages: 1163-1165, ISSN: 0923-7534, DOI: 10.1093/annonc/mdx127
Annals of Oncology 28/6 2020-04-22
2017 Riccardo Ricotta, Antonella Verrioli, Silvia Ghezzi, Luca Porcu, A Grothey, Alfredo Falcone, Eric Van Cutsem, Guillem Argilés, Antoine Adenis, Marc Ychou, Carlo Barone, Olivier Bouché, Marc Peeters, Yves Humblet, Laurent Mineur, Alberto F Sobrero, Joleen M Hubbard, Chiara Cremolini, Hans Prenen, Josep Tabernero, Hajer Jarraya, Thibault Mazard, Sophie Deguelte-Lardiere, Konstantinos Papadimitriou, Marc Van den Eynde, Alessandro Pastorino, Daniela Redaelli, Katia Bencardino, Chiara Funaioli, Alessio Amatu, Giulia Carlo-Stella, Valter Torri, Andrea Sartore-Bianchi, Angelo Vanzulli, Salvatore Siena
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)
published pages: e000111, ISSN: 2059-7029, DOI: 10.1136/esmoopen-2016-000111
ESMO Open 1/6 2020-04-22
2017 Nabil Amirouchene-Angelozzi, Charles Swanton, Alberto Bardelli
Tumor Evolution as a Therapeutic Target
published pages: 805-817, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-17-0343
Cancer Discovery 7/8 2020-04-22
2017 Giulia Siravegna, Elena Geuna, Benedetta Mussolin, Giovanni Crisafulli, Alice Bartolini, Danilo Galizia, Laura Casorzo, Ivana Sarotto, Maurizio Scaltriti, Anna Sapino, Alberto Bardelli, Filippo Montemurro
Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases
published pages: e000253, ISSN: 2059-7029, DOI: 10.1136/esmoopen-2017-000253
ESMO Open 2/4 2020-04-22
2017 Gabriele Picco, Consalvo Petti, Alessia Centonze, Erica Torchiaro, Giovanni Crisafulli, Luca Novara, Andrea Acquaviva, Alberto Bardelli, Enzo Medico
Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions
published pages: 293-303, ISSN: 1757-4676, DOI: 10.15252/emmm.201606773
EMBO Molecular Medicine 9/3 2020-04-22
2016 S. Arena, G. Siravegna, B. Mussolin, J. D. Kearns, B. B. Wolf, S. Misale, L. Lazzari, A. Bertotti, L. Trusolino, A. A. Adjei, C. Montagut, F. Di Nicolantonio, R. Nering, A. Bardelli
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
published pages: 324ra14-324ra14, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aad5640
Science Translational Medicine 8/324 2020-04-22
2016 A. Amatu, L. Barault, C. Moutinho, A. Cassingena, K. Bencardino, S. Ghezzi, L. Palmeri, E. Bonazzina, F. Tosi, R. Ricotta, T. Cipani, P. Crivori, R. Gatto, G. Chirico, G. Marrapese, M. Truini, A. Bardelli, M. Esteller, F. Di Nicolantonio, A. Sartore-Bianchi, S. Siena
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer
published pages: 1062-1067, ISSN: 0923-7534, DOI: 10.1093/annonc/mdw071
Annals of Oncology 27/6 2020-04-22
2016 Beth O. Van Emburgh, Sabrina Arena, Giulia Siravegna, Luca Lazzari, Giovanni Crisafulli, Giorgio Corti, Benedetta Mussolin, Federica Baldi, Michela Buscarino, Alice Bartolini, Emanuele Valtorta, Joana Vidal, Beatriz Bellosillo, Giovanni Germano, Filippo Pietrantonio, Agostino Ponzetti, Joan Albanell, Salvatore Siena, Andrea Sartore-Bianchi, Federica Di Nicolantonio, Clara Montagut, Alberto Bardelli
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
published pages: 13665, ISSN: 2041-1723, DOI: 10.1038/ncomms13665
Nature Communications 7 2020-04-22
2017 Filippo Pietrantonio, Claudio Vernieri, Giulia Siravegna, Alessia Mennitto, Rosa Berenato, Federica Perrone, Annunziata Gloghini, Elena Tamborini, Sara Lonardi, Federica Morano, Benedetta Picciani, Adele Busico, Chiara Costanza Volpi, Antonia Martinetti, Francesca Battaglin, Ilaria Bossi, Alessio Pellegrinelli, Massimo Milione, Chiara Cremolini, Maria Di Bartolomeo, Alberto Bardelli, Filippo de Braud
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
published pages: 2414-2422, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-16-1863
Clinical Cancer Research 23/10 2020-04-22
2017 Alberto Bardelli, Klaus Pantel
Liquid Biopsies, What We Do Not Know (Yet)
published pages: 172-179, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2017.01.002
Cancer Cell 31/2 2020-04-22
2016 D. Oddo, E. M. Sennott, L. Barault, E. Valtorta, S. Arena, A. Cassingena, G. Filiciotto, G. Marzolla, E. Elez, R. M. J. M. van Geel, A. Bartolini, G. Crisafulli, V. Boscaro, J. T. Godfrey, M. Buscarino, C. Cancelliere, M. Linnebacher, G. Corti, M. Truini, G. Siravegna, J. Grasselli, M. Gallicchio, R. Bernards, J. H. M. Schellens, J. Tabernero, J. A. Engelman, A. Sartore-Bianchi, A. Bardelli, S. Siena, R. B. Corcoran, F. Di Nicolantonio
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
published pages: 4504-4515, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-16-0396
Cancer Research 76/15 2020-04-22
2017 Rodrigo Dienstmann, Louis Vermeulen, Justin Guinney, Scott Kopetz, Sabine Tejpar, Josep Tabernero
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
published pages: 79-92, ISSN: 1474-175X, DOI: 10.1038/nrc.2016.126
Nature Reviews Cancer 17/2 2020-04-22
2017 G. Siravegna, A. Sartore-Bianchi, B. Mussolin, A. Cassingena, A. Amatu, L. Novara, M. Buscarino, G. Corti, G. Crisafulli, A. Bartolini, F. Tosi, M. Erlander, F. Di Nicolantonio, S. Siena, A. Bardelli
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor
published pages: , ISSN: 0923-7534, DOI: 10.1093/annonc/mdx095
Annals of Oncology 2020-04-22
2017 Giulia Siravegna, Silvia Marsoni, Salvatore Siena, Alberto Bardelli
Integrating liquid biopsies into the management of cancer
published pages: , ISSN: 1759-4774, DOI: 10.1038/nrclinonc.2017.14
Nature Reviews Clinical Oncology 2020-04-22
2017 Mariangela Russo, Alberto Bardelli
Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies
published pages: a029587, ISSN: 2157-1422, DOI: 10.1101/cshperspect.a029587
Cold Spring Harbor Perspectives in Medicine 7/2 2020-04-22
2017 Takeo Fujii, Afsaneh Barzi, Andrea Sartore-Bianchi, Andrea Cassingena, Giulia Siravegna, Daniel D. Karp, Sarina A. Piha-Paul, Vivek Subbiah, Apostolia M. Tsimberidou, Helen J. Huang, Silvio Veronese, Federica Di Nicolantonio, Sandeep Pingle, Cecile Rose T. Vibat, Saege Hancock, David Berz, Vladislava O. Melnikova, Mark G. Erlander, Rajyalakshmi Luthra, E. Scott Kopetz, Funda Meric-Bernstam, Salvatore Siena, Heinz-Josef Lenz, Alberto Bardelli, Filip Janku
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers
published pages: , ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-16-2592
Clinical Cancer Research 2020-04-22

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MOTRICOLOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MOTRICOLOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More